Bayer AG has been drawing attention from the market regulator due to its share price drop and is under scrutiny, according to sources. The company recently sought approval for a possible capital raise over legal issues. Despite a cautious
FY25 and a Q4 loss, Bayer's stock is up due to growth views starting from FY26. However, the stock hit a 2-decade low due to an outlook cut and 2025 earnings fall forecast, causing significant shareholder dissatisfaction. To tackle ongoing legal woes surrounding the Monsanto Roundup Lawsuit, Bayer is eyeing a potential capital raise which may require the issuance of new stock. Despite various challenges, a Bayer Supervisory Board member purchased shares, this signaling confidence in the company's strategies. Bayer AG's
Q4 results and ABBV's Obesity deal were key highlights in the recent
Pharma Stock Roundup. As the
litigation fears persist, Bayer seeks investor approval for a 35% cash call. Looking into the future, Bayer sees improvement in 2026 after an expected profit decline this year.
BAYER Stocks News Analytics from Tue, 14 May 2024 07:00:00 GMT to Tue, 11 Mar 2025 18:36:02 GMT -
Rating -6
- Innovation -2
- Information 7
- Rumor -9
